AB Science announces that it has filed an application for conditional Marketing Authorization to EMA for masitinib in the treatment of ALS
24/08/2022 – AB Science today announced that it has filed an application for conditional Marketing Authorization to the European Medicines Agency (EMA) for Alsitek (masitinib) in the treatment of amyotrophic lateral sclerosis (ALS)